Aarti Drugs per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹20.93₹21.36₹18.35₹18.56₹17.97
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹20.93₹21.36₹18.35₹18.56₹17.97
₹169.70₹169.70₹149.99₹139.39₹128.77
₹293.37₹281.07₹261.54₹275.03₹293.31
—₹27.78₹26.80₹39.04₹14.49
₹8.79₹8.79₹7.39₹14.42−₹3.29
—₹1.99₹0.99₹1.01₹1.02
9.19.19.19.29.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health
₹ CrorePeersALIVUSAARTIPHARMADVENZYMESAGARWALEYEAKUMSAPLLTDCORONAHCGMcap ₹4,098 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS17.9718.5618.3521.3620.93
Diluted EPS17.9718.5618.3521.3620.93
Book Value per Share128.77139.39149.99169.70169.70
Revenue per Share293.31275.03261.54281.07293.37
Cash Flow per Share14.4939.0426.8027.78—
Free Cash Flow per Share-3.2914.427.398.798.79
Dividends per Share1.021.010.991.99—
Shares Outstanding (cr)9.39.29.19.19.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.